Kintor Pharma eyes regeneration with over-the-counter cosmetic treatments
The Suzhou-based drug developer said it will commercialize its hair-loss product despite disappointing clinical testing results, as it shifts away from cancer drugs Key Takeaways: Kintor announced it will commercialize…
Recent Articles
RELATED ARTICLES
-
Plenty of room for growth in China’s hair transplant market
- Cancer drug maker Genfleet joins Hong Kong IPO influx
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
-
Xuanzhu Biopharm set for spin-off in Hong Kong IPO
0460.HK
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
